Roberto Mina
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos M, Boccadoro M, Quach H, Ho P, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof I, van de Donk N, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hájek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen E, Vanquickelberghe V, Sitthi-Amorn A, Van de Velde C, Carson R, Rodriguez-Otero P, Bladé J, Moreau P, PERSEUS Trial Investigators. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2023; 390:301-313.
Dec 12, 2023Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dec 12, 2023N Engl J Med 2023; 390:301-313
Sonneveld Pieter, Dimopoulos Meletios A, Boccadoro Mario, Quach Hang, Ho P Joy, Beksac Meral, Hulin Cyrille, Antonioli Elisabetta, Leleu Xavier, Mangiacavalli Silvia, Perrot Aurore, Cavo Michele, Belotti Angelo, Broijl Annemiek, Gay Francesca, Mina Roberto, Nijhof Inger, van de Donk Niels W C J, Katodritou Eirini, Schjesvold Fredrik, Sureda Balari Anna, Rosiñol Laura, Delforge Michel, Roeloffzen Wilfried, Silzle Tobias, Vangsted Annette Juul, Einsele Hermann, Spencer Andrew, Hájek Roman, Jurczyszyn Artur, Lonergan Sarah, Ahmadi Tahamtan, Liu Yanfang, Wang Jianping, Vieyra Diego, van Brummelen Emilie M J, Vanquickelberghe Veronique, Sitthi-Amorn Anna, Van de Velde Cornelis J H, Carson Robin, Rodriguez-Otero Paula, Bladé Joan, Moreau Philippe, PERSEUS Trial Investigators
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Ludwig H, Terpos E, van de Donk N, Mateos M, Moreau P, Dimopoulos M, Delforge M, Rodriguez-Otero P, San-Miguel J, Yong K, Gay F, Einsele H, Mina R, Caers J, Driessen C, Musto P, Zweegman S, Engelhardt M, Cook G, Weisel K, Broijl A, Beksac M, Bila J, Schjesvold F, Cavo M, Hájek R, Touzeau C, Boccadoro M, Sonneveld P. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol 2023; 24:e255-e269.
Jun 1, 2023Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Jun 1, 2023Lancet Oncol 2023; 24:e255-e269
Ludwig Heinz, Terpos Evangelos, van de Donk Niels, Mateos Maria-Victoria, Moreau Philippe, Dimopoulos Melitios-Athanasios, Delforge Michel, Rodriguez-Otero Paula, San-Miguel Jesús F, Yong Kwee, Gay Francesca, Einsele Hermann, Mina Roberto, Caers Jo, Driessen Christoph, Musto Pellegrino, Zweegman Sonja, Engelhardt Monika, Cook Gordon, Weisel Katja, Broijl Annemiek, Beksac Meral, Bila Jelena, Schjesvold Fredrik, Cavo Michele, Hájek Roman, Touzeau Cyrille, Boccadoro Mario, Sonneveld Pieter